Catheter Fraud Detection and Prior Authorization: Billing Privileges Without the Orders

For catheter fraud, the Centers for Medicare & Medicaid Services did not require prior authorization for A4351, A4352 or A4353 as of the July 2026 list update. The Master List makes an item eligible for selection, but a separate Required Prior Authorization List determines whether approval is mandatory. The agency had made A4351 eligible without requiring that review.

Who Detected the Catheter Billing Surge?

In its February 2026 enrollment notice, CMS said it had identified a concerning rise in early 2023 involving fifteen medical supply companies that had recently changed ownership. Its investigation found that physicians had not ordered the supplies, beneficiaries had not received them, and the supplies were unnecessary. It stopped payments and revoked those companies’ Medicare enrollments.

CMS’s July 2024 proposed rule identified unusual billing in A4352, the curved-tip catheter code, and A4353, the catheter with insertion supplies. Spending on those codes had stayed below 0.1 percent of Medicare fee-for-service spending from 2016 through 2022, then approached 1 percent in 2023.

The Medicare claims data showed a different pattern for A4351, the straight-tip code: it did not share that surge.

The July rule also credited accountable care organizations with alerting CMS to the effect on their patients’ spending. In a December 2024 rule, CMS said it could determine that the annual increase was significant, anomalous and highly suspect only after 2023 ended.

Then, in its June 2025 criminal takedown announcement, the Justice Department credited its Data Analytics Team and partners with detecting anomalous billing through proactive analysis. Finding a suspect supplier was different from measuring the full year’s damage to accountable care organizations. An insider’s account can connect the billing change to what happened inside the business when it changed hands.

Why Did Catheter Claims Affect ACO Shared Savings?

Catheter claims increased spending attributed to an accountable care organization’s patients, which could reduce its shared savings or increase what it owed Medicare. The organization could bear that cost even though its clinicians had not ordered the supplies. The Centers for Medicare & Medicaid Services acknowledged that these organizations do not process their patients’ claims and cannot cause them to be denied.

An April 2024 coalition letter reported the Institute for Accountable Care’s analysis of the two catheter codes: spending rose from $153 million in 2021 to $3.1 billion in 2023. The organizations responsible for patients’ care could lose savings over supplies their clinicians never ordered and their patients never received.

The effects spread beyond the directly affected accountable care organizations. CMS explained that suspect billing also changed the regional and national spending comparisons used to assess performance. An ACO with little exposure could appear to do better because spending elsewhere had risen. False supplier claims could distort both sides of the comparison.

CMS’s final adjustment took effect October 15, 2024. It removed payment amounts for the two codes from the specified Shared Savings Program calculations for 2023. That corrected how CMS measured ACO performance. Stopping a supplier’s payments and removing its claims from an ACO’s calculation were separate jobs.

Does DME Require Prior Authorization?

CMS prior authorization applies to selected durable medical equipment and supplies. The applicable code, required list and implementation date determine whether that review applies.

CMS’s November 2019 rule, effective January 2020, separates eligibility from requirements. The Master List identifies items that may face added controls. A separate list requires a face-to-face encounter and a written order before delivery. The Required Prior Authorization List requires review before the item is furnished and the claim submitted. An item can face either requirement or both.

For prior authorization, the supplier submits the order, relevant medical records and supplier documentation for a provisional decision. Having an order before delivery and having Medicare review the file before payment are different controls.

A4351 Master List Does Not Mean Required Prior Authorization

CMS expressly defended placing A4351 on the Master List in its November 2019 rule, citing spending and improper-payment criteria. That decision made the straight-tip catheter eligible for selection. Mandatory prior authorization required another decision.

The July 2026 update added other equipment to the required lists. It did not add catheter codes A4351, A4352 or A4353 to the Required Prior Authorization List.

For an employee reviewing a catheter file, the Master List entry answers whether CMS could select that item for a control. The required list and effective date answer whether the control applied to that claim.

What Did the Catheter Code and Claim Have to Show?

The code identifies what the supplier says it furnished. A4351 describes a straight-tip intermittent catheter, A4352 a curved-tip catheter, and A4353 a catheter supplied with insertion supplies. The product, clinical need and delivery each have a place in the payment decision.

The economics help explain why these distinctions deserve attention. In its 2022 catheter pricing study, the Office of Inspector General at the Department of Health and Human Services reported that Medicare and beneficiaries paid $407 million in fiscal year 2020 for catheters suppliers acquired for approximately $121 million. The inspector general recommended lower payment rates while preserving access to the products patients need. The inspector general found room for substantial savings even after allowing for suppliers’ other costs.

What Are Medicare’s Sterile Catheter Kit Requirements?

For Medicare billing, a closed-system catheter description has to match the actual sterile kit and its coverage criteria. A catheter and lubricant packaged separately do not become a kit because the supplier bills the kit code.

Sterile kits also have additional clinical conditions. One qualifying route involves documented recurrent urinary tract infections while using the specified sterile catheterization supplies. The kit designation therefore reaches beyond the packing slip into the patient’s medical record.

How Many Catheters Will Medicare Pay for Per Month?

The Medicare catheter monthly quantity limit for sterile kits is a combined maximum of 200 units for A4297 and A4353. The patient’s medical need and the kit criteria still determine the claim. A billing system’s ability to repeat the maximum quantity says nothing about the quantity the physician ordered or the supplier delivered.

What Are the Documentation Guidelines for Durable Medical Equipment?

Durable medical equipment documentation requirements connect the written order, supporting medical record, product supplied, delivery and refill request. For recurring shipments, CMS’s documentation requirements require the refill request to be documented before shipment. An attestation added afterward does not replace that request.

These are separate records of separate events. The practitioner supports the clinical need. The supplier holds the order and delivery evidence. Refill contact records show whether a new shipment followed an affirmative request. A billing or operations employee may know where those accounts stopped matching.

What Happens If DMEPOS Billing Is Improper?

Medicare can recover overpayments and subject claims to further medical review. The inspector general’s February 2025 catheter audit illustrates the reasons: unsupported eligibility for curved-tip catheters or sterile kits, missing refill support, inadequate proof of delivery and problems with written orders.

The audit covered July 2021 through June 2022, before the surge. It estimated that approximately $35.1 million of the $303.3 million Medicare paid for catheters and kits was improper. Its findings identify the documents a claims total alone cannot explain.

In its 2025 improper-payment report, CMS said many urological-supply errors involved claims under payment suspension for the Justice Department’s Operation Gold Rush prosecution. Those counted as zero-dollar errors and did not contribute to the improper-payment rate. A suspended claim could carry a documentation failure without adding a paid dollar to that rate.

Supplier Ownership, Enrollment and Competitive Bidding

The later controls reached supplier entry and the future market for supplying catheters. They followed the payment suspensions and enrollment revocations already described by CMS.

The criminal indictment described in the Justice Department’s Operation Gold Rush announcement alleged that organizers bought existing medical supply companies with Medicare billing privileges, installed nominee owners and used stolen identities to submit claims. The allegation puts ownership records beside the billing file: the companies already had permission to bill when the alleged organizers acquired them.

The Justice Department’s national announcement put Medicare payments received at approximately $41 million against approximately $4.45 billion scheduled for payment. It said $4.41 billion remained in escrow. Those figures show why the supplier’s payment history matters alongside the claims history.

The Centers for Medicare & Medicaid Services imposed a six-month nationwide enrollment moratorium for medical supply companies beginning February 27, 2026. That measure addressed entry into Medicare by the covered supplier types.

The next competitive-bidding round puts urological supplies and hydrophilic urinary catheters in separate categories within a nationwide Remote Item Delivery program. Medicare will generally pay contract suppliers for those items. CMS’s published target is to begin no later than January 1, 2028. This changes who supplies the products in a future contract period. It did not govern the claims that surged in 2023.

Catheter Kickbacks: Steering Orders Through a Prescription Form

A separate civil catheter case shows why the ordering channel belongs in the inquiry. C.R. Bard agreed to a $17 million settlement announced in January 2025. The government alleged that free samples and discounts encouraged urology practices to use Bard’s prescription form for intermittent catheters. A former employee of another company brought the whistleblower case.

That case concerns how orders were steered. Gold Rush’s indictment concerns the acquisition of billing companies and misuse of identities. Someone inside the business can explain how the order reached the supplier, who controlled the company and what supported the claim. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know What Was Behind the Claim

If you work in catheter billing, enrollment, clinical operations or supply fulfillment, tell our whistleblower experts how the claims diverged from the orders and deliveries. We build the case around what you know about the orders, shipments and people controlling the supplier. We bring in healthcare fraud whistleblower lawyers who understand supplier billing and stay beside you throughout the case.